Webinar: mRNA Is Never Naked, Exploring RBP Target Space & Therapeutic Opportunities
14 Nov 2023
siRNA
mRNA is never caught naked. RNA binding proteins (RBPs), act as vigilant guardians, covering RNA within cells. The role of RBPs is multifaceted, affecting mRNA processing, localization, life-time, and translation, working at steady state or leading to an instantaneous effect on their target mRNA upon stimuli. RBPs constitute an unexplored frontier, specifically implicated in different diseases including cancer, Neurodegeneration, and inflammation. Over the last decade, advancements in this novel target space have brought us to a juncture where the promise of these new therapeutic opportunities is greater than ever.
Watch this webinar to gain insights from expert speakers who have made significant advancements in the field of RBPs:
Definition of an RBP – domains and functional activity
Identification of novel RBPs and RBP-RNA interaction using machine learning
Delve into innovative strategies for discovering RBP modulators
Register to watch
Panelists
Dr. Iris Alroy, PhD
Anima Biotech | Co-Founder and Chief Scientific Officer
Iris Alroy, Ph.D. has over 25 years of experience in drug discovery, preclinical and early clinical development. Dr. Alroy has served as co-founder and CSO of Anima since 2015, supervising drug discovery and pipeline development in the emerging field of mRNA translation regulation. Prior to Anima, she acted as VP of Discovery at Proteologics and Pharmos Corp. and CEO of several startup biotech companies, including Fusimab, Ltd. and ProMining Therapeutics Ltd. Dr. Alroy earned her doctorate in Cell Biology from Cornell University and completed a post-doctoral fellowship at the Weizmann Institute. She has authored more than 20 scientific articles in peer-reviewed journals.
Dr. Kristopher W. Brannan, PhD
Houston Methodist Research Institute, Weill Cornell Medical College | Assistant Professor
Kristopher Brannan is an Assistant Professor and CPRIT Scholar in the Center for RNA Therapeutics and Houston Methodist Cancer Center at the Houston Methodist Research Institute. He received his B.A. degree in molecular, cellular and developmental biology at the University of Colorado Boulder, and his Ph.D. in molecular biology at the University of Colorado School of Medicine. He was a postdoctoral fellow at the University of California San Diego and joined the faculty at the Houston Methodist Research Institute in 2021. His work is focused on RNA-protein interactions that regulate gene expression programs disrupted in cancer and neurological disease.
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
Targets
-Drugs
-Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.